Skip to main content
. 2023 Mar 6;14(4):405–410. doi: 10.1021/acsmedchemlett.2c00449

Table 2. Pharmacodynamic Characteristics of Prodrugs 1c, 1e, and 3d.

graphic file with name ml2c00449_0005.jpg

compound core R1 onset time (s) duration time (s) mean change in MAPmax (%) mean change in heart rate (%)
1c I CH2CH2CH3 265.00 ± 162.39h 1941.90 ± 916.50h 20.07 ± 21.86f –29.92 ± 7.50c
1e I C(CH3)3 157.90 ± 64.68g 3091.80 ± 633.31 14.57 ± 6.32h –27.08 ± 4.96d
3d II CH(CH3)2 239.30 ± 80.84h 3984.10 ± 1077.21 22.40 ± 9.98g –22.88 ± 7.55d
Dex-1a         15.54 ± 4.03h –41.07 ± 8.04
Dex-2b     87.80 ± 38.08 3312.00 ± 556.74 43.55 ± 11.32 –33.58 ± 11.22
a

Rats received dexmedetomidine by intravenous infusion.

b

Rats received dexmedetomidine in a single administration.

c

p < 0.05 versus the Dex-1 group.

d

p < 0.01 versus the Dex-1 group.

e

p < 0.001 versus the Dex-1 group.

f

p < 0.05 versus the Dex-2 group.

g

p < 0.01 versus the Dex-2 group.

h

p < 0.001 versus the Dex-2 group.